View the latest corporate presentation from Capricor.
To view a complete list of our most recent and past events and presentations please click here.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Capricor’s lead candidate, CAP-1002, is a cardiac cell therapy that is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack). Capricor plans to explore development of the exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas.